

Index

A

ABORTIONS

as source of fetal pancreas tissue, 24

ALLOGRAFT REJECTION. *See also* Rejection phenomena

and passenger cells, 23

and pretreatment of islet cells, 11–13, 15–16

susceptibility to, 36–37

theory of, 30–32

ALLOGRAFTS. *See* Islet cell transplantation

ALLOXAN DIABETES

in mice

and reversal of hyperglycemia by intrasplenic transplantation of cultured allogeneic mouse islets, 55–59

ANTIBODIES

anti-DR

and localization of HLA-DR antibodies in human islets of Langerhans, 17–22

and HLA-DR antigens in human fetal pancreas tissue, 23–27, 29

monoclonal, recognizing T-cell antigens and DR-antigens in human fetal pancreas tissue, 26

mouse anti-rat Ia nonpolymorphic monoclonal

rat islets incubated with, and allograft survival time, 48–54

ANTIGENS. *See also under specific types of*

and allogeneic reactivity theory, 30–32

and allograft rejection, 38

in cultured fetal mouse and human pancreas islets, 45

HLA-DR

in human fetal pancreas tissue, 23–27, 29

immunocytochemical localization in human islets of Langerhans, 17–22

and organ culture of fetal pancreatic islets, 45

and influence of removal of passenger cells from skin and parathyroid allografts, 60–61

major histocompatibility complex and allogeneic reactivity, 30–32

and organ culture, 32

and rat islet tissue cultures, 48–54

and stimulation of immune system and susceptibility of established allografts to rejection, 36

ANTILYMPHOCYTE GLOBULIN

and cyclosporin A immunosuppression in kidney transplantation patients, 98–99

and reversal of insulinitis in streptozotocin-diabetic mice, 83

AZATHIOPRINE

and cyclosporin A

and heart allografts in rats, 95

and pancreas allografts in rats, 96

and immunosuppression, 93

B

BLOOD

allogeneic elements of, 2

BONE MARROW CELLS

infusion in rats

and survival of islet cell allografts across major histocompatibility barriers, 63–67

neonatal inoculation in rats

and islet cell transplantation effects on immune insulinitis, 84–88, 90–91

and total lymphoid irradiation transplantation and, 75–77

C

CALCIUM

in culture mediums for islet cells, 57–58

CARBON DIOXIDE. *See* Organ cultures; Tissue cultures

CELLULAR IMMUNE REACTIONS

against pancreatic islet cells, 80–81

COLLAGENASE

and H-2 antigen studies, 9

COLLAGENASE TECHNIQUE

for isolation of pancreas islets, 109

COMPLEMENT

and Ia-antiserum treatment in islet cell-transplanted mice, 15

COMPLEMENT-MEDIATED CYTOTOXICITY ASSAYS

and detection of H-2 antigens on pancreatic β -cells, 1–2

CYTOPHOSPHAMIDE

pretreatment of transplant donors with, 11

and renal transplantation, 38

CYCLOSPORIN A

and immunosuppression, 92–106, 108

complications and side effects in kidney transplantation patients, 99

in human pancreas transplantation, 100–106

and islet cell allografts in rats, 96–97, 98

and kidney transplantation, 98–100

mechanism of action, 92

and pancreas allografts in rats, 95–96, 98

D

DELAYED HYPERSENSITIVITY REACTIONS

and pancreatic islets transplantation in "BB" rats, 90–91

DR-ANTIGENS

-positive cells

in human fetal pancreas tissue, 23–27, 29

DIABETES MELLITUS

insulin-dependent

and potential of pancreatic islets of Langerhans transplantation, 39–46

and pancreas allografts, 84, 88

E

ENDOTHELIAL CELLS

antigens on, 38

of human islet-enriched fractions

localization of HLA-DR antigen in, 20–22

EPIDERMAL LANGERHANS CELLS

and skin allograft rejection, 23

ERYTHROCYTES

H-2 antigens on, 6

mouse

and complement-mediated cytotoxicity assays of H-2 antigens, 1–2

F

FETUS

human and mouse pancreatic islets in organ culture

and allografting studies, 39–46

human pancreas tissue

HLA-DR antigens in, 23–27, 29

rat pancreas transplants

and total lymphoid irradiation, 69–74

G**GLUCOSE TOLERANCE TESTS**

and islet cell transplantation in rats after total lymphoid irradiation and bone marrow cells infusion, 66

GRAFT-VERSUS-HOST DISEASE. *See*

also Rejection phenomena
and use of total lymphoid irradiation in transplantation of rat fetal pancreases, 69–74, 75

H**H-2 ANTIGENS**

and islet β -cell transplants, 16
and mouse islet cells, 12
on surface of mouse pancreatic β -cells
islet cell transplantation and, 1–8, 9–10

HEART ALLOGRAFTS

in rats
and cyclosporin A immunosuppression, 93–95, 98

HEPATOCTES

H-2 antigens and, 9–10

HEREDITY

and expression of major histocompatibility determinants on islets of Langerhans, 12

HLA-DR ANTIGENS

in human fetal pancreas tissues, 23–27, 29
immunocytochemical localization in human islets of Langerhans, 17–22
and organ culture of fetal pancreatic islets, 45

HYPERGLYCEMIA

experimental in mice
and intrasplenic islet cell transplantation, 55–59, 78–82, 83

I**IMMUNE RESPONSES**

theory of, 30–32

IMMUNE SYSTEM

and pancreatic islet transplantation, 30–37
specific and nonspecific stimulation of and susceptibility of established allografts to rejection, 36

IMMUNOCYTOCHEMISTRY

and localization of antigen-bearing cells in rat islets, 52–53
and localization of HLA-DR antigens in human islets of Langerhans, 17–22

IMMUNOFERRITIN-LABELING TECHNIQUE

and H-2 antigens on mouse pancreatic β -cells, 1–8, 12

IMMUNOGENICITY

and fetal pancreas allografts, 35–37
of tissue allografts
organ culture and, 36

IMMUNOPEROXIDASE STAINING

and HLA-DR antigens in human fetal pancreas tissue, 24–27, 29

IMMUNOSUPPRESSION

conventional
in human kidney transplantation, compared with cyclosporin A immunosuppression, 99
in human pancreas transplantation, compared with cyclosporin A immunosuppression, 100–101
and cyclosporin A, 92–106, 108
elimination in islet cell transplantation and pretreatment of islet cells, 11–13, 15–16
elimination by total lymphoid irradiation, 75–77
research in, 93
side effects of
and organ culture of pancreatic islets of Langerhans, 39

INSULIN

production
by cultured fetal mouse and human islets, 42
secretion and content of cultured mouse islets, 56–57

INSULITIS

and damage to transplanted pancreatic islets, 84–88
experimental in mice
and intrasplenic islet cell transplantation, 78–82, 83
spontaneous immune in rats
and islet cell transplantation and neonatal bone marrow cell inoculation, 84–88, 90–91

INTERNATIONAL HUMAN PANCREAS AND ISLET TRANSPLANTATION REGISTRY

report through 1981, 112–15

IRRADIATION. *See* Total lymphoid irradiation**ISLET CELL TRANSPLANTATION**

and allogeneic reactivity theory, 31–32
of cultured adult mouse islets, 32–35
reversal of hyperglycemia by, 55–59
of cultured fetal islet cells
and reversal of diabetes, 35–37
of cultured islet cells
prolongation of survival and, 48–54
of fetal islets
and HLA-DR antigens, 23–27, 29
and H-2 antigens on mouse pancreatic β -cells, 1–8, 9–10
intrasplenic
in mice with experimental insulinitis and hyperglycemia, 78–82, 83
in mice
and elimination of immunosuppression with pretreatment of islets, 11–13, 15–16
and reversal of diabetes, 32–37

and organ culture of fetal mouse and human islets, 39–46

in rats

across major histocompatibility barriers, total lymphoid irradiation and allogeneic bone marrow cell infusion and, 63–67
and cyclosporin A immunosuppression, 96–97, 98
in rats with immune insulinitis
and bone marrow cell neonatal inoculation, 84–88, 90–91
report of International Human Pancreas and Islet Transplantation Registry on, 112–115
strain-specific maintenance and rejection in mice, 13
and susceptibility of established allografts to rejection, 36–37
and theory of allogeneic reactivity, 30–32
and tolerance compared with enhancement, 15–16
xenogeneic
and reversal of diabetes, 35

ISLETS OF LANGERHANS. *See also* Islet cell transplantation

human
immunocytochemical localization of HLA-DR in, 17–22
isolation from beef and pig pancreas
new method for, 109–111
mouse
isolation of, 2

K**KIDNEY TRANSPLANTATION**

and cyclosporin A immunosuppression, 98–100
mechanism of long-term survival, 15
in rats
and prevention of rejection, 38
results of pancreas transplants and, 114
and total lymphoid irradiation and bone marrow conditioning, 67

KIDNEYS

islet cell transplantation under capsule of, 32–37

L**LEUKOCYTES**

passenger
and tissue rejection, 2

LYMPHOCYTES

H-2 antigens on, 9
infiltration into pancreatic islets of streptozotocin-diabetic mice, 80–81

LYMPHOID CELLS. *See also* Total lymphoid irradiation

la-bearing
and rejection phenomena, 12–13

M

MAJOR HISTOCOMPATIBILITY COMPLEX

- and influence of passenger cell removal from skin and parathyroid allografts, 60–61
- islet cell transplantation across and total lymphoid irradiation, 63–67
- fetal pancreas transplantation across and total lymphoid irradiation, 69–74, 75–77

METABOLISM

- of cyclosporin A and conventionally treated pancreas transplantation patients, 102–105

METHYLPREDNISOLONE

- and cyclosporin A in kidney transplantation, 99

MICE

- adult and fetal cultured islet cell transplantation and reversal of diabetes, 32–37
- allografted
 - establishment and induction of tolerance in, 36–37
- with experimental insulinitis and hyperglycemia
 - and intrasplenic islet cell transplantation, 78–82, 83
- fetal pancreatic islets for allotransplantation, 39–46
- H-2 antigens on pancreatic β -cells of islet cell transplantation and, 1–8
- islet cell transplantation of cultured allogeneic islets and reversal of hyperglycemia by, 55–59
- islet cell transplantation without immunosuppression in
 - and pretreatment of islets, 11–13, 15–16
- organ cultured fetal pancreas
 - islet cell transplantation with, 35–37
- skin allografting in
 - effects of passenger cell removal, 60–61

MICROSCOPY

- of cultured mouse islet tissue, 33
- electron
 - and DR localization in human islets of Langerhans, 20–21
 - of freshly isolated and cultured rat pancreatic islets, 49–52
 - and H-2 antigens on pancreatic β -cells, 3
- electron immunocytochemistry
 - and localization of DR antigen in human islets of Langerhans, 19–20
- of human fetal pancreas tissue
 - and HLA-DR antigens, 24–26
- of intrasplenic transplants of allogeneic islets, 58
- of islets isolated by new method, 11, 111
- light
 - and DR localization in human islets of Langerhans, 20
 - of fetal pancreatic islets, 40–45
 - of intrasplenic syngeneic islets im-

- planted into streptozotocin-diabetic mice, 81
- of pancreatic islets of streptozotocin-diabetic mice, 80

MIXED LYMPHOCYTE REACTION

- as delayed-type hypersensitivity reaction, 90–91
- and epidermal Langerhans cells, 23
- and immunosuppressive effect of total lymphoid irradiation, 77
- and islet cell allografting, 45–46
- and islet cell graft maintenance or rejection in mice, 13
- and removal of passenger cells from skin and parathyroid allografts in rats and mice, 61

N

NEPHROTOXICITY

- and cyclosporin immunosuppression in kidney transplantation patients, 99

O

ORGAN CULTURE

- and allograft survival, 11–12
- and fetal islet cells
 - reversal of diabetes and, 35–37
- of fetal mouse and human pancreatic islets
 - and allografting, 39–46
 - and immunogenicity of thyroid tissue, 31–32

OXYGEN

- and organ culture of fetal mouse and fetal human pancreatic islets for allografting, 39–46
- and pretreatment of islet cells transplantation without immunosuppression, 11–13, 15–16

P

PANCREAS

- beef and pig
 - new method for isolation of islets from, 109–111
- fetal
 - changes in culture, 40–42
 - and culture in high concentrations of oxygen, 42
 - morphology of, 40
- human fetal
 - HLA-DR antigens in, 23–27, 29
- insulin
 - and islet cell transplantation and H-2 antigens study in mice, 6
- islet-enriched fractions, isolation of, 17
- mouse β -cell transplantation
 - and H-2 antigens, 1–8, 9–10

PANCREAS TRANSPLANTATION

- in humans
 - and cyclosporin A immunosuppression, 100–106

- rat fetal
 - and total lymphoid irradiation, 69–74
- in rats
 - and cyclosporin A immunosuppression, 95–96, 98
 - report of International Human Pancreas and Islet Transplantation Registry on, 112–115

PARATHYROID ALLOGRAFTS

- in rats
 - and effects of passenger cell removal, 60–61

PASSENGER CELLS. See also Passenger leukocytes; Passenger lymphocytes

- and rejection phenomena, 16, 23
- removal from skin and parathyroid allografts in mice and rats, 60–61

PASSENGER LEUKOCYTES

- and rejection phenomena, 17, 31–32

PASSENGER LYMPHOCYTES

- and rat models of renal transplantation, 38
- and rejection phenomena in thyroid allograft model, 11

PEROXIDASE-ANTIPEROXIDASE STAINING

- and localization of HLA-DR antigens, 18–19

PREDNISONE

- and cyclosporin A immunosuppression and heart allografts in rats, 94–95
- in kidney transplantation patients, 99
- in pancreas transplantation patients, 100–101
- and immunosuppression, 93

R

RADIOIMMUNOBINDING ASSAYS

- of cultured rat islets of Langerhans, 52

RATS

- "BB" spontaneously diabetic
 - and pancreatic islets transplantation, 84–88, 90–91
- cultured islets of Langerhans allografts
 - and reduction of Ia-antigen-bearing cells and prolongation of allograft survival, 48–54
- fetal pancreas transplantation
 - and total lymphoid irradiation, 69–74
- heart allografts in
 - and cyclosporin A immunosuppression, 93–94, 98
- with immune insulinitis
 - islet cell transplantation and neonatal bone marrow cell inoculation in, 84–88, 90–91
- islet cell allografts in
 - and cyclosporin A immunosuppression, 96–97, 98
- islet cell transplantation across major histocompatibility barriers
 - and total lymphoid irradiation and allogeneic bone marrow cells infusion, 63–67

- pancreas allografts in
and cyclosporin A immunosuppression and, 95–96, 98
- parathyroid allografts in
effects of passenger cell removal, 60–61
- spontaneously diabetic
and allogeneic islet transplantation, 34–35

REJECTION PHENOMENA. *See also* Allograft rejection; Survival and Ia-like antigens, 17 and cytotoxic antibodies, 38 of islet allografts tissue culture reduction of, 48–54 and passenger leukocytes, 2 susceptibility of established islet cell allografts to, 36–37

S

S-PARENCHYMAL CELLS

- antigen-bearing
and response to tissue allografts, 31–32

SERUM

- anti-Ia
and rejection phenomena, 12–13
and survival of islet cell transplantation, 15

SKIN ALLOGRAFTS

- in mice
and effects of passenger cell removal, 60–61
rejection mechanism, 15
rejection of, 2, 16
and passenger cells, 23

SPLEEN

- intrasplenic islet cell transplantation, 57
in mice with experimental insulinitis and hyperglycemia, 78–82, 83
leukocytes
and localization of HLA-DR in human islets of Langerhans, 17–22

STAPHYLOCOCCAL PROTEIN A

- radiolabeled
and detection of HLA-DR antigens, 18

STREPTOZOTOCIN DIABETES

- in mice
and H-2 antigens in islet cell transplantation studies, 3–8
reversal by allogeneic islet transplantation, 33–34
and survival of intrasplenically implanted islets, 78–82, 83
- in rats
and islet cell transplantation after total lymphoid irradiation and bone marrow cells infusion, 63–67
and use of total lymphoid irradiation in transplantation of rat fetal pancreases, 69–74

SURVIVAL. *See also* Rejection phenomena

- and immunosuppression with cyclosporin A, 92–106, 108
of intrasplenically implanted islets in mice with insulinitis and hyperglycemia, 78–82, 83
and pancreas transplantation patients immunosuppression and, 102
of skin and parathyroid allografts in mice and rats
and removal of passenger cells, 60–61

T

THYMOCYTES

- antigens on, 9

THYROID ALLOGRAFTS

- and in vitro culture prior to transplantation, 11
and passenger leukocytes, 17
in mice, 6–7
and organ culture, 31–32

TISSUE CULTURE

- of allogeneic mouse islets
reversal of hyperglycemia after transplantation of, 55–59
and islet allografts, 109
of rat pancreatic islets
and reduction of Ia-antigen-bearing cells and prolongation of allograft survival, 48–54

TISSUES

- distribution of Ia-like antigens in, 17

TOLERANCE

- compared with enhancement, 15–16
establishment and induction in allografted animals, 36–37
induction with bone marrow cells, 84–88, 90–91

TOTAL LYMPHOID IRRADIATION

- and heart allografts in rats
cyclosporin A and, 95
and rat fetal pancreas transplantation, 69–74
and survival of islet cell allografts in rats
across major histocompatibility barriers, 63–67
and transplantation, 75–77

TRANSPLANTATION. *See also under specific type of*
and immunosuppression with cyclosporin A, 92–106, 108

TRYPSIN

- and isolation of H-2 antigens, 9

V

VASCULAR ENDOTHELIAL CELLS

- and allograft rejection, 23–24, 32
and organ culture, 36

VELCRO STRIPS

- and new method for isolation of islets, 109–111